AbbVie’s newer immunology drugs are offsetting Humira’s decline, sending
stock up 4%
-
AbbVie’s earnings topped estimates as it offered an upbeat view of 2025.
13 minutes ago
North America 2007 SUMMER in MAY //usa2007blogspot.com
No comments:
Post a Comment